Live Analyst Rating Changes 21390 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gregory Renza
TRU

Gregory Renza

Truist Financial
Wall Street Analyst
★★★☆☆
#1727
on 13Foresight · ranked by our own returns
58%
Success Rate
+1.8%
Average Return
59 of 102 calls profitable · -3.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 58% of Gregory Renza's ratings turned a profit when each position was held for 1 year — averaging +1.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

194 Buy 22 Hold 0 Sell
Gregory's Stock Coverage 37 ratings · 2026-08-09
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VRDN
Viridian Therapeutics
 Aug 07, 2026 BUY Strong Buy
+49.2% avg upside
32 analysts
$39.00
65.38% Upside
 +0.0% ·
CGON
CG Oncology, Inc.
 Aug 07, 2026 BUY Strong Buy
+14.4% avg upside
17 analysts
$85.00
13.16% Upside
 · ·
GMAB
Genmab
 Aug 07, 2026 BUY Strong Buy
+14.8% avg upside
27 analysts
$40.00
27.91% Upside
 +0.0% ·
NUVB
Nuvation Bio
 Aug 07, 2026 BUY Strong Buy
+103.3% avg upside
15 analysts
$13.00
96.91% Upside
 · ·
ZYME
Zymeworks
 Aug 07, 2026 BUY Strong Buy
+40.2% avg upside
25 analysts
$32.00
36.03% Upside
 · ·
MNKD
MannKind
 Aug 06, 2026 BUY Buy
+71.1% avg upside
22 analysts
$6.00
45.91% Upside
 · ·
RVMD
Revolution Medicines
 Aug 06, 2026 BUY Strong Buy
-20.2% avg upside
32 analysts
 — +3.7% ·
ONC
BeOne Medicines
 Aug 06, 2026 BUY Strong Buy
+3.6% avg upside
28 analysts
$418.00
20.10% Upside
 +5.3% ·
XNCR
Xencor
 Aug 06, 2026 BUY Strong Buy
+66.8% avg upside
27 analysts
 — +0.0% ·
EXEL
Exelixis
 Aug 06, 2026 HOLD Buy
-19.3% avg upside
34 analysts
$52.00
3.78% Downside
 +3.6% ·
AMGN
Amgen
 Aug 05, 2026 HOLD Buy
-23.6% avg upside
57 analysts
$362.00
12.00% Downside
 +0.8% ·
IDYA
IDEAYA Biosciences
 Aug 05, 2026 BUY Strong Buy
+31.3% avg upside
29 analysts
$59.00
59.28% Upside
 +0.5% ·
GILD
Gilead Sciences
 Aug 05, 2026 BUY Strong Buy
-10.7% avg upside
66 analysts
$150.00
12.54% Upside
 +1.1% ·
JAZZ
Jazz Pharmaceuticals
 Aug 04, 2026 BUY Strong Buy
-7.8% avg upside
35 analysts
$264.00
2.94% Upside
 -1.9% ·
REGN
Regeneron
 Jul 31, 2026 BUY Strong Buy
-0.1% avg upside
58 analysts
$772.00
1.51% Downside
 +2.9% ·
FULC
Fulcrum Therapeutics
 Jul 31, 2026 HOLD Hold
+126.7% avg upside
14 analysts
$4.00
2.86% Upside
 +8.7% ·
BCYC
Bicycle Therapeutics
 Jul 31, 2026 HOLD Strong Buy
+462.9% avg upside
21 analysts
$7.00
67.93% Upside
 +8.0% ·
AGIO
Agios Pharma
 Jul 31, 2026 BUY Strong Buy
+88.9% avg upside
29 analysts
$39.00
20.89% Upside
 +7.5% ·
VKTX
Viking Therapeutics
 Jul 30, 2026 BUY Strong Buy
+110.8% avg upside
31 analysts
$83.00
142.34% Upside
 +3.5% ·
NRIX
Nurix Therapeutics
 Jul 10, 2026 BUY Strong Buy
+25.6% avg upside
28 analysts
$34.00
33.11% Upside
 +9.4% ·
ABVX
Abivax SA Sponsored ADR
 Jul 02, 2026 BUY Strong Buy
+2.6% avg upside
15 analysts
$155.00
18.47% Upside
 -9.5% ·
CATX
Perspective Therapeutics
 May 12, 2026 BUY Strong Buy
+274.0% avg upside
22 analysts
 — -20.4% ·
AAPG
Ascentage Pharma Group International Unsponsored ADR
 Apr 24, 2026 BUY Strong Buy
+146.5% avg upside
10 analysts
$51.00
168.71% Upside
 -28.6% ·
ACAD
ACADIA Pharmaceuticals
 May 19, 2025 BUY Strong Buy
+24.7% avg upside
43 analysts
$26.00
10.99% Downside
 -6.9% ·
ADCT
ADC Therapeutics
 May 14, 2025 BUY Buy
+431.0% avg upside
12 analysts
$8.00
607.94% Upside
 +85.6% ·
INO
Inovio Pharmaceuticals
 May 13, 2025 HOLD Buy
+1197.1% avg upside
19 analysts
$5.00
648.45% Upside
 -30.2% ·
VRCA
Verrica Pharmaceuticals
 May 13, 2025 HOLD Strong Buy
+259.9% avg upside
8 analysts
$20.00
293.69% Upside
 +34.0% ·
VSTM
Verastem
 May 13, 2025 BUY Strong Buy
+126.2% avg upside
24 analysts
$16.00
137.41% Upside
 -36.7% ·
JSPR
Jasper Therapeutics
 May 12, 2025 BUY Strong Buy
+4286.9% avg upside
17 analysts
$46.00
6383.51% Upside
 -80.8% ·
PCRX
Pacira Pharmaceuticals
 May 08, 2025 HOLD Buy
+56.2% avg upside
21 analysts
$26.00
3.86% Upside
 -7.1% ·
ATYR
aTyr Pharma
 May 07, 2025 BUY Buy
+1539.9% avg upside
17 analysts
$16.00
3028.71% Upside
 -70.8% ·
SPRB
Spruce Biosciences
 May 06, 2025 HOLD Strong Buy
+123.8% avg upside
15 analysts
$37.50
20.06% Downside
 -85.5% ·
CRMD
Cormedix
 May 06, 2025 BUY Strong Buy
+101.0% avg upside
13 analysts
$13.00
74.78% Upside
 -27.9% ·
AVTX
Avalo Therapeutics
 Jun 26, 2023 HOLD Strong Buy
+185.2% avg upside
20 analysts
$180.00
882.50% Upside
 -89.1% ·
APRE
Aprea Therapeutics
 Mar 16, 2022 HOLD Buy
+3416.3% avg upside
7 analysts
$80.00
12202.05% Upside
 · ·
ITRMF
Iterum Therapeutics
 Nov 12, 2021 HOLD Buy
+71666566.6% avg upside
5 analysts
$15.00
149999899.91% Upside
 · ·
BIIB
Biogen
 Sep 08, 2015 BUY Strong Buy
+21.6% avg upside
52 analysts
$348.00
67.38% Upside
 -0.3% ·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Gregory Renza — Frequently Asked Questions
How accurate are Gregory Renza's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Gregory's ratings were profitable over a one-year hold, with an average return of +1.8% per rating, or -3.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Gregory ranked on 13Foresight?
Gregory Renza is currently ranked #1727 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gregory cover?
Gregory most recently has ratings on VRDN, CGON, GMAB, NUVB, ZYME, MNKD, RVMD, ONC, XNCR, EXEL, AMGN, IDYA and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.